Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

The Impact of Biophoton Therapy on Self-Grown Stem Cells

NCT06855459 · View on ClinicalTrials.gov ↗

Study Summary

Study Objective The purpose of this clinical study is to evaluate if biophoton therapy, delivered by Tesla BioHealing® Biophoton Generators (Biophotonizer), can increase self-grown stem cells naturally. Study Design This is a randomized, double-blinded, placebo-controlled intervention clinical study to assess the effectiveness of biophoton therapy in impacting stem cells. Approximately 46 volunteers who want to increase self-grown stem cells will participate in the study. Study Randomization The biostatistician will prepare a randomization schedule including a serial of subject numbers. A subject number will be randomly assigned to each study participant, which will assign them to either the control group or the treatment group. Other than the Informed Consent Form (ICF), all study information will be recorded by using the subject number. The Principal Investigator, study physicians, study nurse, data-entry specialists, and biostatisticians, as well as the participants, will be blinded about who received which product during the first two weeks of study participation.

Interventions

  • DEVICE Biophoton Generators

Study Locations (2)

Florida

  • Tesla MedBed at Tampa-FL — Tampa

Pennsylvania

  • Tesla BioHealing Wellness Hotel - Butler-PA — Butler

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2025-02-10
Est. Completion 2026-03-30
Phase NA

Sponsor

First Institute of All Medicines

32 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06855459

The ClinicalTrials.gov registry entry for NCT06855459 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is First Institute of All Medicines, which has 32 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Inflammation appearing as the primary indexed condition, and to 1 intervention — of which Biophoton Generators is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06855459 reports 2 study locations spanning 2 distinct geographic areas — top geographies include Florida, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06855459 about?

NCT06855459 is a clinical study titled "The Impact of Biophoton Therapy on Self-Grown Stem Cells". Study Objective The purpose of this clinical study is to evaluate if biophoton therapy, delivered by Tesla BioHealing® Biophoton Generators (Biophotonizer), can increase self-grown stem cells naturally. Study Design This is a randomized, double-blinded, placebo-controlled intervention clinical stud...

What is the current status of trial NCT06855459?

This trial is currently recruiting. It is a NA study. The enrollment target is 46 participants. The study started on 2025-02-10. Estimated completion is 2026-03-30.

What conditions does trial NCT06855459 study?

This clinical trial studies the following conditions: Inflammation, Increase the Total Number of Stem Cells. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06855459?

The interventions under investigation include: Biophoton Generators (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06855459?

This trial is sponsored by First Institute of All Medicines, which has 32 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06855459 being conducted?

This trial has 2 study locations across Florida, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial